Collaborative Programs

Joining Forces to Advance Treatments for Neurodegenerative Diseases

Inhibikase’s business model is two-pronged: demonstrating clinical proof-of-concept in target populations while simultaneously developing first-in-class and best-in-class medications. We intend to commercialize our novel medications, either alone or in partnership, to achieve the best outcome for patients on the shortest timescale possible.

In meeting our primary commitment to patients with neurodegenerative diseases that have little to no treatment options, we collaborate with academic research teams and other third parties to drive our discovery efforts and advance the product candidates in our pipeline.

Ongoing Collaborations

We currently have ongoing collaborations with The Johns Hopkins University, Memorial Sloan-Kettering Cancer Center, the Medical College of Wisconsin,Arizona State University and the University of Bordeaux.

Collaborate with Us

We welcome all questions and comments regarding our collaborative programs

Connect with Us